Current Concepts and Unmet Needs in Psoriatic Arthritis

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2017 Nov 15

PMID 29134513

Citations 11

Authors

Farrouq Mahmood

Laura C Coates

Philip S Helliwell

Affiliations

Soon will be listed here.

Abstract

Psoriatic arthritis is a chronic inflammatory arthritis that is part of the spondyloarthropathy group of rheumatic diseases and has associated co-morbidities. It can present with various clinical manifestations making diagnosis and treatment challenging, resulting in significant disability and reduced quality of life for patients. Whilst there have been advances in understanding the pathogenic mechanisms of the disease which have resulted in targeted therapies, there is still the need for further studies as some patients fail or are intolerant of current therapies. Better identification of early disease and knowledge of prognostic markers would enable clinicians to initiate appropriate therapy with the expectation that early aggressive treatment will minimise joint damage progression. Improved knowledge of the condition would also enable clinicians to better tailor specific treatment strategies for each of the various clinical domains in psoriatic arthritis.

Citing Articles

Differences between psoriatic arthritis and psoriasis in multi-omics.

Gao S, Song H Arch Dermatol Res. 2024; 316(6):217.

PMID: 38787526 DOI: 10.1007/s00403-024-03018-9.

Bimekizumab: A Review in Psoriatic Arthritis.

Nie T, Shirley M Drugs. 2024; 84(5):587-598.

PMID: 38703349 DOI: 10.1007/s40265-024-02026-3.

Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis.

De Vlam K, Mease P, Bushmakin A, Fleischmann R, Ogdie A, Azevedo V Rheumatol Ther. 2022; 9(5):1451-1464.

PMID: 36076054 PMC: 9510078. DOI: 10.1007/s40744-022-00482-5.

Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.

Kokolakis G, Vadstrup K, Hansen J, Carrascosa J Dermatology. 2021; 238(4):620-629.

PMID: 34823247 PMC: 9393840. DOI: 10.1159/000520290.

From Bed to Bench and Back: TNF-α, IL-23/IL-17A, and JAK-Dependent Inflammation in the Pathogenesis of Psoriatic Synovitis.

Silvagni E, Missiroli S, Perrone M, Patergnani S, Boncompagni C, Bortoluzzi A Front Pharmacol. 2021; 12:672515.

PMID: 34211394 PMC: 8241099. DOI: 10.3389/fphar.2021.672515.

References

Gladman D . Recent advances in understanding and managing psoriatic arthritis. F1000Res. 2016; 5:2670. PMC: 5115220. DOI: 10.12688/f1000research.9592.1. View

Coates L, Aslam T, Balushi F, Burden A, Burden-Teh E, Burden-The E . Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol. 2013; 168(4):802-7. DOI: 10.1111/bjd.12190. View

Kavanaugh A, Mease P, Gomez-Reino J, Adebajo A, Wollenhaupt J, Gladman D . Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014; 73(6):1020-6. PMC: 4033106. DOI: 10.1136/annrheumdis-2013-205056. View

Gill T, Asquith M, Rosenbaum J, Colbert R . The intestinal microbiome in spondyloarthritis. Curr Opin Rheumatol. 2015; 27(4):319-25. PMC: 4489849. DOI: 10.1097/BOR.0000000000000187. View

Mease P, Armstrong A . Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014; 74(4):423-41. PMC: 3958815. DOI: 10.1007/s40265-014-0191-y. View

Mease P, Van den Bosch F, Sieper J, Xia Y, Pangan A, Song I . Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. J Rheumatol. 2017; 44(5):599-608. DOI: 10.3899/jrheum.160387. View

Raychaudhuri S, Wilken R, Sukhov A, Raychaudhuri S, Maverakis E . Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun. 2016; 76:21-37. DOI: 10.1016/j.jaut.2016.10.009. View

Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou C . The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2010; 70(1):25-31. DOI: 10.1136/ard.2010.133645. View

Marchesoni A, Lubrano E, Cauli A, Ricci M, Manara M . Psoriatic Disease: Update on Traditional Disease-modifying Antirheumatic Drugs. J Rheumatol Suppl. 2015; 93:61-4. DOI: 10.3899/jrheum.150639. View

10.

Haroon M, Gallagher P, FitzGerald O . Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2014; 74(6):1045-50. DOI: 10.1136/annrheumdis-2013-204858. View

11.

Mease P, Gottlieb A, van der Heijde D, FitzGerald O, Johnsen A, Nys M . Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017; 76(9):1550-1558. PMC: 5561378. DOI: 10.1136/annrheumdis-2016-210724. View

12.

Kerschbaumer A, Fenzl K, Erlacher L, Aletaha D . An overview of psoriatic arthritis - epidemiology, clinical features, pathophysiology and novel treatment targets. Wien Klin Wochenschr. 2016; 128(21-22):791-795. PMC: 5104808. DOI: 10.1007/s00508-016-1111-9. View

13.

Callis Duffin K, Chandran V, Gladman D, Krueger G, Elder J, Rahman P . Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol. 2008; 35(7):1449-53. PMC: 2724000. View

14.

Palazzi C, Olivieri I, DAmico E, DAgostino L, Nicolucci A, Pennese E . Hepatitis C virus infection in psoriatic arthritis. Arthritis Rheum. 2005; 53(2):223-5. DOI: 10.1002/art.21079. View

15.

Siebert S, Porter D, Paterson C, Hampson R, Gaya D, Latosinska A . Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. Sci Rep. 2017; 7:40473. PMC: 5320079. DOI: 10.1038/srep40473. View

16.

Nograles K, Brasington R, Bowcock A . New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol. 2009; 5(2):83-91. PMC: 2790861. DOI: 10.1038/ncprheum0987. View

17.

Huynh D, Kavanaugh A . Psoriatic arthritis: current therapy and future approaches. Rheumatology (Oxford). 2014; 54(1):20-8. DOI: 10.1093/rheumatology/keu237. View

18.

Congi L, Roussou E . Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin Exp Rheumatol. 2010; 28(3):304-10. View

19.

Ritchlin C, Colbert R, Gladman D . Psoriatic Arthritis. N Engl J Med. 2017; 376(10):957-970. DOI: 10.1056/NEJMra1505557. View

20.

Haroon M, Winchester R, Giles J, Heffernan E, FitzGerald O . Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis. 2014; 75(1):155-62. DOI: 10.1136/annrheumdis-2014-205461. View